A. R. Gray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. R. Gray has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
A. G. Ortega‐Loayza
Department of Dermatology Oregon Health and Science University Portland OR USA
1 shared publication- Kevin White
Department of Dermatology, Oregon Health & Science University, Portland, OR
1 shared publication - Olivia M. T. Davies
Department of Dermatology, Brigham and Women’s Hospital, Boston, MA
1 shared publication
Latest Publications
- 28 January 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (5) , 924-926
Granuloma annulare following initiation of interleukin‐17a antagonist
The introduction of biologics has rapidly expanded treatment options for patients suffering from severe plaque psoriasis. Currently, the mainstay of biologic therapy for psoriasis centers around three key classes: Anti‐tumor necrosis factor (TNF), Anti‐Interleukin (IL)‐23, and Anti‐IL‐17, such as Secukinumab and Ixekizumab. Though generally considered to have favorable safety profiles, there have been growing reports of dermatologic adverse events in the setting of biologic therapy initiation.
- 28 January 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (5) , 924-926
Granuloma annulare following initiation of interleukin‐17a antagonist
The introduction of biologics has rapidly expanded treatment options for patients suffering from severe plaque psoriasis. Currently, the mainstay of biologic therapy for psoriasis centers around three key classes: Anti‐tumor necrosis factor (TNF), Anti‐Interleukin (IL)‐23, and Anti‐IL‐17, such as Secukinumab and Ixekizumab. Though generally considered to have favorable safety profiles, there have been growing reports of dermatologic adverse events in the setting of biologic therapy initiation.